We do a lot of work in pharma and in financial services and they have more in common than you might imagine.

Both sectors face increasing competition and we’re working on an evidence-based approach to strategy development that works in both.

In pharma, patents are expiring at an unprecedented rate, allowing generic alternatives to flood the market wiping millions from the bottom line overnight. In banking, regulation separating retail from investment operations and the growth and encouragement of smaller and new banks is threatening the historical domination of larger organisations.

The end result for both sectors is an ever more pressing need to allocate marketing budgets more wisely and that means informing strategy with insights gained from the analysis of customer data and learning from what did and didn’t work in the past.

You’d be forgiven for assuming that global household-name businesses did this already.



The words “chaos” and “opportunity” are the same in Chinese according to Michael Reilly of Triantan Solutions, one of the expert speakers at the recent PharmaTimes’ Round Table event on Digital on 28th June.

Come 2020, when brand new Chinese-made smart phones are being given out for $10 to many millions in Africa, we in ‘The West” might look back and wish we had taken a bit more notice in 2011. (more…)

Next Page »